BRANNING TODD P. (Chief Financial Officer) purchased 50.0% of their position (10K shares) of NEUBASE THERAPEUTICS, INC. on the open market
Open‑market purchase worth $18.1K — a major conviction buy. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 3/21/2022ACC: 0001104659-22-036105
Officer· Chief Financial Officer
Since Jan 2022
+10K
Net shares
Net buyer
$18.1K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
10K acquired
Non-Derivative Transactions1
Common stock
Direct
Shares
+10K
Price / share
$1.81
Trade value
$18.10K
% of position
50.0%
3/18/2022
20K→30K
Total
Net shares
+10K
Net value
$18.10K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common stock Direct | 3/18/2022 | P · Purchase | +10K | $1.81 | $18.10K | 50.0% | 20K | 30K |
| Total | +10K | $18.10K | ||||||
Derivative Transactions0
No derivative transactions reported